Loading page…

Supriya Lifescience Limited (SUPRIYA) · mywealthgrid

Supriya Lifescience Limited

NSE:SUPRIYA BSE:SUPRIYA

HealthcarePharmaceuticals & BiotechnologyNIFTY MICROCAP 250 +1

₹930.7

-2.12%2 Oct, 9:00 am

Mkt cap

₹7,495 Cr

Watch Alert Compare

About

Supriya Lifescience: mid-sized pharma company (₹6,372 Cr market cap) with zero debt. Quarterly revenue grew from ₹160.63 Cr (Jun 2024) to ₹276.53 Cr (Mar 2026) with sustained 35%+ operating margins. ROE 19.06% shows efficient capital use.

Face value: ₹2

Market cap

₹7,495 Cr

P/E

37.8×

P/B

6.3×

Dividend yield

0.1%

ROE

19.1%

ROCE

24.5%

Debt / equity

OPM

35.5%

EPS (TTM)

₹24.6

Book value

₹148.8

52-week high

—

52-week low

—

Key insights

Company research notes and source-linked reviews

Key risks

PE 30.47 elevated; limited downside if growth slows
Quarterly revenue volatile ₹145 Cr (Jun 2025) to ₹276.53 Cr (Mar 2026); verify concentration in products or customers
Promoter 68.3% stake; limits minority influence, amplifies execution risk
OPM 35%+ (high for pharma); verify if structural advantages or exposed to competitive/cost pressures

Generated analysis · source review pending

Growth drivers

Mar 2026 revenue ₹276.53 Cr (34% above Dec 2025); verify if sustainable
Net profit ₹74.23 Cr (26.9% net margin) on 70% revenue growth over 2 years; verify margin sustainability and capital deployment plans
Zero debt (D/E 0) enables M&A, capex, R&D; verify management's deployment strategy
Revenue growth from ₹160.63 Cr (Jun 2024) to ₹276.53 Cr (Mar 2026) despite Jun 2025 dip; verify if driven by new products, markets, or volume

Generated analysis · source review pending

1,173 historical price candles were omitted because the exchange source has not been verified.

₹930.7-5.5%1Y

Quick read

rule-based

Pros

+Strong return on equity of 18.5% (3-yr avg)
+High return on capital employed of 24.2%
+Healthy operating margin of 35.5%
+Revenue CAGR of 16.2% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 146.6×
+High promoter holding of 68.3% with no pledge

Cons

−Low dividend payout of 4.1% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

64/100

Business quality: 84
Growth: 72
Valuation: 36

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	391	530	461	570	696	828
COGS	128	196	181	222	211	254
Gross profit	263	334	280	349	485	574
	90	120	151	176	225	280
	173	214	129	173	261	294
OPM %	44.3%	40.4%	28%	30.3%	37.4%	35.5%
Depreciation	7	10	12	16	20	28
Interest	4	4	3	2	2	2
	5	8	9	11	10	11
Profit before tax	167	207	123	166	248	275
Tax	44	55	34	47	61	66
Tax %	26.1%	26.8%	27.2%	28.1%	24.4%	23.9%
	124	152	90	119	188	209
PAT margin %	31.6%	28.6%	19.5%	20.9%	27%	25.3%
EPS (₹)	16.9	18.9	11.2	14.8	23.4	26
EPS adjusted (₹)	16.9	18.9	11.2	14.8	23.4	26
	0%	3.2%	5.4%	5.4%	4.3%	3.8%
Annual report	—	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	15	16	16	16	16	16
Reserves	254	600	683	799	981	1,182
	70	21	17	0	0	0
	107	98	104	106	116	159
Total equity & liabilities	445	735	820	921	1,112	1,357
	100	190	256	305	453	685
CWIP	79	43	68	149	148	36
Investments	0	0	25	64	63	99
	267	502	471	403	448	538
Total assets	445	735	820	921	1,112	1,357

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	76	49	66	113	165	186
	-47	-60	-133	-174	-152	-176
	-15	150	-3	-22	-8	-10
Net cash flow	15	139	-70	-83	4	-0
Free cash flow	28	-11	-42	-32	2	34
CFO / Operating profit %	43.8%	22.8%	51.4%	65.5%	63.1%	63.2%

Compounded sales growth

7 years: —
5 years: 16%
3 years: 22%
1 year: 19%

Compounded profit growth

7 years: —
5 years: 11%
3 years: 33%
1 year: 11%

Return on equity

7 years: —
5 years: 18%
3 years: 17%
Last year: 18%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	67.2%	63.1%	60.8%	61.1%	69.7%	69.3%
EBITDA margin %	44.3%	40.4%	28%	30.3%	37.4%	35.5%
EBIT margin %	42.5%	38.5%	25.4%	27.6%	34.5%	32.1%
PAT margin %	31.6%	28.6%	19.5%	20.9%	27%	25.3%
Working capital
Receivable days	69	79	67	71	70	97
Inventory days	206	172	234	140	205	229
Payable days	145	91	130	98	0	159
NWC days	130	160	171	114	275	167
Leverage
Current ratio	1.82	4.99	4.85	5.17	5.32	4.4
Debt to EBITDA	0.41	0.1	0.13	0	0	0
Debt to equity	0.26	0.03	0.02	0	0	0
Interest coverage	42	50.3	41.1	79.5	148	146.6
Asset turnover	0.88	0.72	0.56	0.62	0.63	0.61
Return ratios
Return on assets %	27.7%	20.7%	11%	12.9%	16.9%	15.4%
Return on capital employed %	57.2%	45.3%	18.6%	21.4%	26.7%	24.5%
Return on equity %	46%	24.7%	12.8%	14.6%	18.9%	17.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%	68.3%
	5.34%	4.56%	5.36%	4.95%	6.03%	6.52%	7.19%	6.78%	5.46%	5.2%	5.16%	6.19%
	7.17%	5.39%	5.3%	5.48%	5.45%	4.92%	4.26%	4.86%	5.22%	5.01%	5.7%	5.3%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	19.19%	21.75%	21.04%	21.27%	20.22%	20.26%	20.25%	20.06%	21.02%	21.49%	20.84%	20.21%
No. of shareholders	—	—	—	—	—	—	—	—	87,912	85,099	81,161	82,082

Promoter holding up 0 percentage points since Sep 2023.

35 deals · 28 Dec 2021 – 22 Nov 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
22 Nov 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	5,85,068	₹784.79	₹45.92 Cr
22 Nov 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	5,85,068	₹785.02	₹45.93 Cr
12 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	6,58,285	₹488.61	₹32.16 Cr
12 Aug 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	6,58,285	₹488.59	₹32.16 Cr
8 Feb 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	6,27,793	₹342.32	₹21.49 Cr
8 Feb 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	6,27,793	₹342.21	₹21.48 Cr
26 Dec 2023	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	4,56,665	₹312.40	₹14.27 Cr
26 Dec 2023	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	4,56,665	₹312.26	₹14.26 Cr
12 May 2023	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	4,03,147	₹248.38	₹10.01 Cr
12 May 2023	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	4,03,147	₹248.48	₹10.02 Cr

1–10 of 35

1 / 4

Mr. Satish Waman WaghExecutive Director-Chairperson
Mrs. Smita Satish WaghExecutive Director
Ms. Saloni Satish WaghExecutive Director-MD
Ms. Shivani Satish WaghExecutive Director-MD
Mr. Balasaheb Gulabrao SawantExecutive Director
Ms. Neelam Yashpal AroraNon-Executive - Independent Director
Mr. Ganapati Dadasaheb YadavNon-Executive - Independent Director
Mr. Sunil Subhash BhagwatNon-Executive - Independent Director
Mr. Manish Ishwarlal PanchalNon-Executive - Independent Director
Mr. Kothandaraman HariNon-Executive - Independent Director
Mr. Krishna RaghunathanChief Financial Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 4 fund houses

Held by these funds

0.53%

of the company's equity

All mutual funds

1.29%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

8 schemes · 4 fund houses

		Shares
(LIVE SCHEMES)	ITI Mutual Fund	1.28 L	10.26	1.41%	0.16%	-0
Small Cap Fund	Quantum Mutual Fund	1.09 L	8.72	3.29%	0.136%	+2,676
(LIVE SCHEMES)	ITI Mutual Fund	91,519	7.31	1.58%	0.114%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	66,556	5.31	0.21%	0.083%	-1,457
(LIVE SCHEMES)	ITI Mutual Fund	27,984	2.23	0.81%	0.035%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	706	0.06	0.13%	0.001%	+1
IB18-Groww Nifty Total Market Index Fund	Groww Mutual Fund	455	0.04	0.01%	0.001%	+2
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	76	0.01	0.01%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Intimation on Credit Rating to the Company is enclosed.30 Dec 2025

Investor Presentation and earnings call

Aug 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

5

Final dividend4 Sept 2026 · ex-date₹1
Final dividend4 Sept 2025 · ex-date₹1
Final dividend20 Sept 2024 · ex-date₹0.8
Final dividend15 Sept 2023 · ex-date₹0.6
Final dividend1 Sept 2022 · ex-date₹0.6

1

Board meeting to consider results13 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

45 announcementsExport CSV

28 Sept 2026, 3:32 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

20 Sept 2026, 11:41 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

11 Sept 2026, 4:46 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

2 Sept 2026, 6:22 pmCompany Update

Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company

General PDF

2 Sept 2026, 5:32 pmCompany Update

Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015.

General PDF

2 Sept 2026, 5:24 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

1 Sept 2026, 8:04 pmOthers

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Reporting (BRSR) PDF

1 Sept 2026, 7:55 pmAGM/EGM

Notice Of 18Th Annual General Meeting Of The Company.

AGM PDF

Date	Category	Subject	Filing
28 Sept 2026, 3:32 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
20 Sept 2026, 11:41 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	67.2%	63.1%	60.8%	61.1%	69.7%	69.3%
EBITDA margin %	44.3%	40.4%	28%	30.3%	37.4%	35.5%
EBIT margin %	42.5%	38.5%	25.4%	27.6%	34.5%	32.1%
PAT margin %	31.6%	28.6%	19.5%	20.9%	27%	25.3%
Working capital
Receivable days	69	79	67	71	70	97
Inventory days	206	172	234	140	205	229
Payable days	145	91	130	98	0	159
NWC days	130	160	171	114	275	167
Leverage
Current ratio	1.82	4.99	4.85	5.17	5.32	4.4
Debt to EBITDA	0.41	0.1	0.13	0	0	0
Debt to equity	0.26	0.03	0.02	0	0	0
Interest coverage	42	50.3	41.1	79.5	148	146.6
Asset turnover	0.88	0.72	0.56	0.62	0.63	0.61
Return ratios
Return on assets %	27.7%	20.7%	11%	12.9%	16.9%	15.4%
Return on capital employed %	57.2%	45.3%	18.6%	21.4%	26.7%	24.5%
Return on equity %	46%	24.7%	12.8%	14.6%	18.9%	17.5%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Supriya Lifescience Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends5

Board meetings1

Announcements

Ratio timeline

Dividends5

Board meetings1

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

5

1

5

1